3.0.0 164 2023-01-11T13:46:42Z 2023-01-11T13:46:42Z Senate S 2021-02-02 117 sshr00 Health, Education, Labor, and Pensions Committee Senate Standing Discharged from 2021-03-03T22:48:43Z Referred to 2021-02-02T20:10:12Z Lower Costs, More Cures Act of 2021 117 19 HR 2021-10-19 Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law. Related bill CRS Advancing Education on Biosimilars Act of 2021 117 1873 HR 2021-03-16 Referred to the Subcommittee on Health. Identical bill CRS 2021-04-23 Became Public Law No: 117-8. President E40000 9 Library of Congress 2021-04-23 Became Public Law No: 117-8. BecameLaw 36000 9 Library of Congress 2021-04-23 Signed by President. President E30000 9 Library of Congress 2021-04-23 Signed by President. BecameLaw 36000 9 Library of Congress 2021-04-20 Presented to President. Floor E20000 2 House floor actions 2021-04-20 Presented to President. President 28000 9 Library of Congress 2021-04-14 17:51:54 Motion to reconsider laid on the table Agreed to without objection. Floor H38310 2 House floor actions 2021-04-14 17:51:53 On motion to suspend the rules and pass the bill Agreed to by the Yeas and Nays: (2/3 required): 412 - 8 (Roll no. 101). (text: CR H1754) Floor H37300 2 House floor actions 101 https://clerk.house.gov/evs/2021/roll101.xml House 117 2021-04-14T21:51:53Z 1 2021-04-14 17:51:53 Passed/agreed to in House: On motion to suspend the rules and pass the bill Agreed to by the Yeas and Nays: (2/3 required): 412 - 8 (Roll no. 101).(text: CR H1754) Floor 8000 9 Library of Congress 101 https://clerk.house.gov/evs/2021/roll101.xml House 117 2021-04-14T21:51:53Z 1 2021-04-14 17:20:52 Considered as unfinished business. (consideration: CR H1783-1784) Floor H30000 2 House floor actions 2021-04-14 13:17:23 At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed. Floor H37220 2 House floor actions 2021-04-14 13:11:22 DEBATE - The House proceeded with forty minutes of debate on S. 164. Floor H8D000 2 House floor actions 2021-04-14 13:11:20 Considered under suspension of the rules. (consideration: CR H1754-1755) Floor H30000 2 House floor actions 2021-04-14 13:10:54 Mr. Pallone moved to suspend the rules and pass the bill. Floor H30300 2 House floor actions 2021-03-08 14:24:33 Held at the desk. Floor H15000 2 House floor actions 2021-03-08 14:16:24 Received in the House. Floor H14000 2 House floor actions 2021-03-08 Senate Message on Senate action sent to the House. Floor 2021-03-03 Senate Passed Senate without amendment by Unanimous Consent. (text: CR S1021) Floor 2021-03-03 Passed/agreed to in Senate: Passed Senate without amendment by Unanimous Consent.(text: CR S1021) Floor 17000 9 Library of Congress 2021-03-03 sshr00 Health, Education, Labor, and Pensions Committee Senate Senate Committee on Health, Education, Labor, and Pensions discharged by Unanimous Consent. (consideration: CR S1021) Discharge 2021-03-03 Senate Committee on Health, Education, Labor, and Pensions discharged by Unanimous Consent.(consideration: CR S1021) Committee 14500 9 Library of Congress sshr00 Health, Education, Labor, and Pensions Committee 2021-02-02 sshr00 Health, Education, Labor, and Pensions Committee Senate Read twice and referred to the Committee on Health, Education, Labor, and Pensions. IntroReferral 2021-02-02 Introduced in Senate IntroReferral 10000 9 Library of Congress H001076 Sen. Hassan, Margaret Wood [D-NH] Maggie Hassan D NH N C001075 Sen. Cassidy, Bill [R-LA] Bill Cassidy R LA 2021-02-02 True Public Law 117-8 Health Drug safety, medical device, and laboratory regulation Government information and archives Health personnel Licensing and registrations Medical education Prescription drugs Health 00 2021-02-02 Introduced in Senate 2021-03-17T15:10:11Z Advancing Education on Biosimilars Act of 2021

This bill requires the Food and Drug Administration (FDA) to advance education and awareness among health care providers about biological products as appropriate, including by developing or improving continuing education programs that address the prescribing of biological products and biosimilars. (A biosimilar is a biological product that is highly similar to an FDA-approved reference biological product and has no clinically meaningful differences from that reference product.)

The FDA may also maintain and operate a website to provide educational materials about biological products.

]]> 55 2021-03-03 Passed Senate 2021-03-17T20:44:49Z Advancing Education on Biosimilars Act of 2021

This bill requires the Food and Drug Administration (FDA) to advance education and awareness among health care providers about biological products as appropriate, including by developing or improving continuing education programs that address the prescribing of biological products and biosimilars. (A biosimilar is a biological product that is highly similar to an FDA-approved reference biological product and has no clinically meaningful differences from that reference product.)

The FDA may also maintain and operate a website to provide educational materials about biological products.

]]> 53 2021-04-14 Passed House 2021-04-19T20:38:44Z Advancing Education on Biosimilars Act of 2021

This bill requires the Food and Drug Administration (FDA) to advance education and awareness among health care providers about biological products as appropriate, including by developing or improving continuing education programs that address the prescribing of biological products and biosimilars. (A biosimilar is a biological product that is highly similar to an FDA-approved reference biological product and has no clinically meaningful differences from that reference product.)

The FDA may also maintain and operate a website to provide educational materials about biological products.

]]> 49 2021-04-23 Public Law 2021-05-06T13:46:19Z Advancing Education on Biosimilars Act of 2021

This bill requires the Food and Drug Administration (FDA) to advance education and awareness among health care providers about biological products as appropriate, including by developing or improving continuing education programs that address the prescribing of biological products and biosimilars. (A biosimilar is a biological product that is highly similar to an FDA-approved reference biological product and has no clinically meaningful differences from that reference product.)

The FDA may also maintain and operate a website to provide educational materials about biological products.

]]> Advancing Education on Biosimilars Act of 2021 Display Title Advancing Education on Biosimilars Act of 2021 Official Title as Introduced A bill to educate health care providers and the public on biosimilar biological products, and for other purposes. Introduced in Senate IS Short Title(s) as Introduced Advancing Education on Biosimilars Act of 2021 Introduced in Senate IS Short Title(s) as Passed Senate Advancing Education on Biosimilars Act of 2021 S Senate Engrossed in Senate ES Short Titles as Enacted Advancing Education on Biosimilars Act of 2021 Short Titles as Passed House Advancing Education on Biosimilars Act of 2021 H House Short Titles as Passed Senate Advancing Education on Biosimilars Act of 2021 S Senate Enrolled Bill https://www.govinfo.gov/content/pkg/BILLS-117s164enr/xml/BILLS-117s164enr.xml Engrossed in Senate 2021-03-03T05:00:00Z https://www.govinfo.gov/content/pkg/BILLS-117s164es/xml/BILLS-117s164es.xml Introduced in Senate 2021-02-02T05:00:00Z https://www.govinfo.gov/content/pkg/BILLS-117s164is/xml/BILLS-117s164is.xml 2021-04-24T03:59:59Z https://www.govinfo.gov/content/pkg/PLAW-117publ8/xml/PLAW-117publ8.xml Public Law 2021-04-23 Became Public Law No: 117-8. text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. Congressional Research Service, Library of Congress This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.